The trajectory of companies tied to flagship drugs like Viagra presents a complex investment scenario . While the initial surge of copyright, fueled by Viagra's extraordinary popularity, generated substantial returns, the loss of exclusivity in key regions has introduced substantial uncertainty . Investors are now assessing the impact of rival medi